7 Major Markets Epidermolysis Bullosa Epidemiology Forecasts Report, 2020-2024 & 2034 - ResearchAndMarkets.com

The "Epidermolysis Bullosa - Epidemiology Forecast - 2034" report has been added to ResearchAndMarkets.com's offering.

The report delivers an in-depth understanding of Epidermolysis Bullosa, historical and forecasted epidemiology trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The report provides historical as well as forecasted epidemiology segmented by total prevalent cases of Epidermolysis Bullosa, total diagnosed prevalent cases of Epidermolysis Bullosa, gender-specific cases of Epidermolysis Bullosa, age-specific cases of Epidermolysis Bullosa, and type-specific cases of Epidermolysis Bullosa in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan from 2020 to 2034.

• The total prevalent cases of Epidermolysis Bullosa in the 7MM comprised approximately 46,800 cases in 2023 and are projected to increase during the forecast period (2024-2034).
• The United States contributed to the largest prevalent cases of Epidermolysis Bullosa i.e., 31,000 cases of in 2023.
• Among EU4 countries in 2023, Germany had the highest prevalence of Epidermolysis Bullosa, followed by Italy.
• In Japan, the age group of >19 years accounted for the least number of cases i.e., around 400 cases in 2023.

Key Highlights

• Epidermolysis Bullosa is slightly more prevalent in males than females, with approximately 14,000 cases reported in the US in 2023.
• In 2023, the majority of type-specific cases were attributed to Epidermolysis Bullosa Simplex. Dystrophic Epidermolysis Bullosa accounted for 30% of prevalent cases, while Junctional Epidermolysis Bullosa constituted just 5% of the observed cases.
• In 2023, Japan accounted for approximately 4% of the Epidermolysis Bullosa cases among the 7MM.
• Among Epidermolysis Bullosa cases in the US in 2022, individuals aged 0-9 years represented approximately 45% of the reported cases.

Scope of the Report

• The report covers a segment of key events, an executive summary, descriptive overview of Epidermolysis Bullosa, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
• Comprehensive insight into the epidemiology segments and forecasts, disease progression has been provided.
• The report provides an edge while developing business strategies, understanding trends, expert insights/KOL views, and patient journeys in the 7MM.
• A detailed review of current challenges in establishing the diagnosis.

Epidermolysis Bullosa Report Insights

• Patient Population
• Country-wise Epidemiology Distribution
• Age-wise Cases of Epidermolysis Bullosa
• Type-specific Cases of Epidermolysis Bullosa

Epidermolysis Bullosa Report Key Strengths

• Eleven Years Forecast
• The 7MM Coverage
• Epidermolysis Bullosa Epidemiology Segmentation

Epidermolysis Bullosa Report Assessment

• Current Diagnostic Practices
• Unmet Needs

Key Topics Covered:

1. Key Insights

2. Report Introduction

3. Executive Summary of Epidermolysis Bullosa (EB)

4. Epidemiology Forecast Methodology

5. Epidermolysis Bullosa Epidemiology Overview at a Glance

5.1. Patient Share (%) of Epidermolysis Bullosa in 2020

5.2. Patient Share (%) of Epidermolysis Bullosa in 2034

6. Epidermolysis Bullosa (EB): Disease Background and Overview

6.1. Introduction

6.2. Causes of Epidermolysis Bullosa

6.3. Signs and Symptoms of Epidermolysis Bullosa

6.4. Pathogenesis of Epidermolysis Bullosa

6.5. Pathophysiology of Itch in Epidermolysis Bullosa Skin

6.6. Classification of Epidermolysis Bullosa

6.7. Genetic Bases of Epidermolysis Bullosa

6.8. Diagnosis of Epidermolysis Bullosa

6.8.1. Types of Laboratory Referral

6.8.1.1. Neonate With Skin Fragility

6.8.1.2. Pediatric and Adult Patients With Skin Fragility

6.8.1.3. Carrier Testing

6.8.1.4. Prenatal Diagnosis

6.8.2. Further Testing

6.8.2.1. Skin Biopsy

6.8.2.2. Molecular Testing

6.8.2.3. Genetic Testing for Epidermolysis Bullosa

6.8.2.3.1. Next-generation Sequencing (NGS) Targeted Gene Panel and Whole-exome Sequencing in Epidermolysis Bullosa

6.8.2.3.2. Sanger Sequencing (SS)

7. Epidemiology and Patient Population of the 7MM

7.1. Key Findings

7.2. Assumption and Rationale

7.3. Total Prevalent Cases of Epidermolysis Bullosa in the 7MM

7.4. Diagnosed Prevalent Cases of Epidermolysis Bullosa in the 7MM

7.5. The United States

7.5.1. Total Prevalent Cases of Epidermolysis Bullosa in the United States

7.5.2. Diagnosed Prevalent Cases of Epidermolysis Bullosa in the United States

7.5.3. Gender-specific Cases of Epidermolysis Bullosa in the United States

7.5.4. Age-specific Cases of Epidermolysis Bullosa in the United States

7.5.5. Type-specific Cases of Epidermolysis Bullosa in the United States

7.6. EU4 and the UK

7.7. Japan

8. Patient Journey

9. Appendix

For more information about this report visit https://www.researchandmarkets.com/r/in6m28

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250418634521/en/